Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: Pancreatic cancer (PC) represents a substantial public health burden. Pancreatic cancer patients have very low survival due to the difficulty of identifying cancers early when the tumour is localised to the site of origin and treatable. Recent progress has been made in identifying biomarkers for PC in the blood and urine, but these cannot be used for population-based screening as this would be prohibitively expensive and potentially harmful. Methods: We conducted a case-control study using prospectively-collected electronic health records from primary care individually-linked to cancer registrations. Our cases were comprised of 1,139 patients, aged 15–99 years, diagnosed with pancreatic cancer between January 1, 2005 and June 30, 2009. Each case was age-, sex- and diagnosis time-matched to four non-pancreatic (cancer patient) controls. Disease and prescription codes for the 24 months prior to diagnosis were used to identify 57 individual symptoms. Using a machine learning approach, we trained a logistic regression model on 75% of the data to predict patients who later developed PC and tested the model’s performance on the remaining 25%. Results: We were able to identify 41.3% of patients < = 60 years at ‘high risk’ of developing pancreatic cancer up to 20 months prior to diagnosis with 72.5% sensitivity, 59% specificity and, 66% AUC. 43.2% of patients >60 years were similarly identified at 17 months, with 65% sensitivity, 57% specificity and, 61% AUC. We estimate that combining our algorithm with currently available biomarker tests could result in 30 older and 400 younger patients per cancer being identified as ‘potential patients’, and the earlier diagnosis of around 60% of tumours. Conclusion: After further work this approach could be applied in the primary care setting and has the potential to be used alongside a non-invasive biomarker test to increase earlier diagnosis. This would result in a greater number of patients surviving this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · cited 1×
“Diagnostic biomarkers [10–14] have been actively sought for a number of years, and the most promising results have been obtained using protein markers [15–17] either alone or in combination with the clinically established biomarker, CA 19–9 [18].”
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841 · cited 1×
“Population-based screening for pancreatic cancer is not a viable option due to the very low incidence (32, 202 and 300/100,000 amongst persons 40–59, 60–79 and 80–99 years respectively) [7,8] resulting in a prohibitively expensive, and even potentially damaging programme [1,9].”
BackgroundAdvanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790 · cited 1×
“Progress to increase the proportion of cancers diagnosed at an early enough stage has been extremely slow [5,6].”
BackgroundProbability of Pancreatic Cancer Following Diabetes: A Population-Based Study
Chari, S. T., Leibson, C. L., Rabe, K. G., Ransom, J., de Andrade, M., & Petersen, G. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.007 · Cited by 603 · cited 1×
“A notable result was the relative importance of diabetes, over timevarying symptoms, in predicting later pancreatic cancer diagnosis, which is consistent with previous research [31].”
ResultEarly detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482
Self-citationMicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
Schultz, N. A., Dehlendorff, C., Jensen, B. V., Bjerregaard, J. K., Nielsen, K. R., Bojesen, S. E., Calatayud, D., Nielsen, S. E., Yilmaz, M., Holländer, N. H., et al. (2014) · JAMA · doi:10.1001/jama.2013.284664 · Cited by 450
Carrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C., & Parthenaki, I. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-015-9724-1 · Cited by 270
Lennon, A. M., Wolfgang, C. L., Canto, M. I., Klein, A. P., Herman, J. M., Goggins, M., Fishman, E. K., Kamel, I., Weiss, M. J., Diaz, L. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0734 · Cited by 262
MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
Daoud, A. Z., Mulholland, E. J., Cole, G., & McCarthy, H. O. (2019) · BMC Cancer · doi:10.1186/s12885-019-6284-y · Cited by 215
Research works printed but not linked: 1
- Team R., 2020, RStudio: Integrated Development for R. RStudio
Cited by
A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories
Placido, D., Yuan, B., Hjaltelin, J. X., Zheng, C., Haue, A. D., Chmura, P. J., Yuan, C., Kim, J., Umeton, R., Antell, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02332-5 · Cited by 349
Artificial intelligence in pancreatic cancer
Huang, B., Huang, H., Zhang, S., Zhang, D., Shi, Q., Liu, J., & Guo, J. (2022) · Theranostics · doi:10.7150/thno.77949 · Cited by 142
“Their method could indicate cancer risk over a decade before diagnosing PC patients [256].”
MethodEarly Detection of Pancreatic Cancer: Applying Artificial Intelligence to Electronic Health Records
Kenner, B. J., Abrams, N., Chari, S. T., Field, B. F., Goldberg, A. E., Hoos, W. A., Klimstra, D. S., Rothschild, L. J., Srivastava, S., Young, M. R., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001882 · Cited by 66
Karar, M. E., El-Fishawy, N. A., & Radad, M. A. (2023) · Journal of Biological Engineering · doi:10.1186/s13036-023-00340-0 · Cited by 61
“Such population-based studies improve awareness of PDAC risk and recommend patients for more diagnostic procedures like bio-marker testing and medical image scanning [4].”
BackgroundRisk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review
Chandana, S. R., Woods, L. M., Maxwell, F., Gandolfo, R., & Bekaii‐Saab, T. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113471 · Cited by 55
Self-citation
Metadata
- Authors
- Malhotra, A., Rachet, B., Bonaventure, A., Pereira, S. P., & Woods, L. M.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Inserm (FR)
- University College London (GB)
- Corresponding author
- Malhotra, Ananya
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-02
- Volume
- 16
- Issue
- 6
- Pages
- e0251876
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8171946
- OpenAlex
- W3164089558
- Cited by
- 56
- References
- 26
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 8 · 2023: 15 · 2022: 9 · 2021: 7
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pancreatic Cancer Research Fund
- UCLH Biomedical Research Centre
- Fondation ARC pour la Recherche sur le Cancer (PDF20190508759)
- Cancer Research UK (C7923/A18525, C23409/A11415)
- Department of Health's National Institute for Health Research Biomedical Research Centres
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
- Keywords
- pancreatic cancer, cancer screening, early diagnosis, risk prediction, primary care, electronic health records, symptom-based prediction, logistic regression, non-invasive biomarkers, cancer registration, elderly patients
- MeSH terms
- Machine Learning, Adolescent, Adult, Aged, Aged, 80 and over, Algorithms, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pancreatic Neoplasms, Primary Health Care, Prognosis, Prospective Studies, Survival Rate, Case-Control Studies, Risk Assessment, Early Detection of Cancer, Young Adult, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data. https://app.cochat.ai/papers/10.1371/journal.pone.0251876
- The paper
- Malhotra, A., Rachet, B., Bonaventure, A., Pereira, S. P., & Woods, L. M. (2021). Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data. PLOS ONE. https://doi.org/10.1371/journal.pone.0251876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.